Drug Profile
Type 5 cyclic nucleotide phosphodiesterase inhibitor - Takeda
Alternative Names: PDE5 inhibitor - Nycomed; PDE5 inhibitor - TakedaLatest Information Update: 11 Apr 2012
Price :
$50
*
At a glance
- Originator Nycomed
- Developer Takeda Pharmaceuticals International GmbH
- Class
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 01 Apr 2012 Discontinued - Phase-I for Respiratory tract disorders in Europe (unspecified route)
- 30 Sep 2011 Nycomed has been acquired by Takeda
- 14 Oct 2009 Phase-I clinical trials in Respiratory tract disorders in Europe (unspecified route)